We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




ECCMID Congress Name Changes to ESCMID Global

By LabMedica International staff writers
Posted on 11 Apr 2024

Over the last few years, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) has evolved remarkably. More...

The society is now stronger and broader than ever before in the four decades since it was founded. Currently, ESCMID is focusing on stepping up the fight against antimicrobial resistance, advancing preparedness for emerging infections, and leading in the practice, education, and training of specialists. In recent years, ESCMID has welcomed over 4000 new members and expects to see a record-breaking 20,000 colleagues attend its congress in Barcelona. Hence, the organization feels the need to adapt to this new reality.

In 2023, ESCMID’s in-depth analysis of its brand and communication efforts revealed that the brand failed to adequately reflect ESCMID’s expanding global role. The analysis also revealed that most community members were unaware of various activities undertaken by ESCMID related to research, education, and guidelines. Additionally, most of its audience was unaware of the connection between the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and ESCMID. As a result, the society has now decided to strengthen its main brand, ESCMID, and bring all of its various sub-brands more closely together under one large ESCMID umbrella. This includes changing the name of its congress to “ESCMID Global”, creating a clear link to ESCMID, and conveying its outreach and perspective beyond Europe.

Simultaneously, ESCMID is modernizing its visual identity. As the society strives for pioneering research and state-of-the-art education, it also aims to communicate in an effective manner that will be suitable to the present time and also apt for the next decade. As a first step in these efforts, the organization has released its renewed website escmid.org. The upcoming ESCMID Global, formerly ECCMID, in Barcelona (27–30 April 2024) will be the society’s 34th congress and the first one with the new name and look.

Related Links:
ESCMID


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.